Compare SHO & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHO | PGEN |
|---|---|---|
| Founded | 1995 | 1998 |
| Country | United States | United States |
| Employees | 37 | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | N/A | 2013 |
| Metric | SHO | PGEN |
|---|---|---|
| Price | $11.36 | $5.55 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $9.79 | $8.33 |
| AVG Volume (30 Days) | 3.1M | ★ 5.7M |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.66% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $230,981,000.00 |
| Revenue This Year | $3.95 | $1,115.92 |
| Revenue Next Year | $2.30 | $81.04 |
| P/E Ratio | $966.33 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.52 | $1.47 |
| 52 Week High | $12.07 | $6.04 |
| Indicator | SHO | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 49.80 | 62.94 |
| Support Level | $8.81 | $3.90 |
| Resistance Level | $12.07 | N/A |
| Average True Range (ATR) | 0.26 | 0.33 |
| MACD | -0.11 | 0.06 |
| Stochastic Oscillator | 23.04 | 69.02 |
Sunstone Hotel Investors Inc is a real estate investment trust that acquires, owns, manages, and renovates the full-service hotel and select-service hotel properties across various states in the United States. Its firm's portfolio consists upper upscale and luxury hotels located in convention, resort destination and urban markets. Its majority of the hotels operate under a brand owned by Marriott, Hilton, Hyatt, Four Seasons or Montage. It operates geographically in California which generates the majority of its revenue; Florida; and Hawaii. The company's sole source of income is hotel revenue from its Hotel Ownership Segment.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.